Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Targeting oncogenes is key for novel cancer therapies.
• MDM2 and MYCN are implicated in various cancers, including neuroblastoma.
• High-risk neuroblastoma has a poor prognosis despite improved survival rates.

Purpose of the Study:

• To review the oncogenic properties and regulation of MYCN.
• To summarize therapeutic strategies targeting MYCN.
• To highlight the potential of dual MYCN and MDM2 inhibition.

Main Methods:

• Literature review of preclinical findings.
• Analysis of molecular regulation of MYCN.
• Evaluation of combined MYCN and MDM2 targeting strategies.

Main Results:

• MYCN dysregulation is linked to tumorigenesis, particularly neuroblastoma.
• Preclinical evidence supports the efficacy and safety of targeting both MYCN and MDM2.
• Small molecules inhibiting both oncogenes show promise.

Conclusions:

• Targeting MYCN and MDM2 is a viable therapeutic strategy for neuroblastoma.
• Dual inhibition offers a novel approach for aggressive neoplasms.
• Further development of small molecules for combined inhibition is warranted.